About CJC-1295 Prescribed: An Editorial Platform Overview
What this site is. What it is not. Why the 'prescribed' modifier in the domain reads as specification, not authorization.
What this site is
CJC-1295 Prescribed reads the peer-reviewed record on CJC-1295 the way an engineer reads a spec sheet — feature by feature. It lays the indexed phase-1 evidence (chiefly Teichman 2006 and the follow-on pharmacokinetic, proteomic, and preclinical work) next to the regulatory file (the FDA 2023 503A Pharmacy Compounding Advisory Committee briefing) and the WADA Prohibited List entry, and presents the whole as a specification overview. No clinic sits behind it and no clinician staffs it; it hands out no dose, no diagnosis, and no product. It reads the papers and specifies what they say — nothing more.
On the domain name
The 'prescribed' modifier in cjc1295prescribed.com is intended in its older sense — set out as a specification — rather than its commercial sense of authorization for use. CJC-1295 is not FDA-approved for any indication, and this site does not describe a prescribing relationship, recommend a course of treatment, or refer readers to clinicians who would. The modifier is editorial framing — a position the publisher occupies relative to the literature. What is prescribed here is the structure of the overview: thirty residues, four substitutions, one optional linker, a half-life that runs in days or in minutes depending on which variant the literature is discussing. The site reads as a specification sheet for the research record, not as a recommendation.
Editorial method
Every quantitative claim on every page traces back to a numbered citation in the references index. Phase-1 dose ranges, half-life figures, IGF-1 fold-change values, proteomic shifts, and the regulatory timeline are each anchored to a specific published paper, FDA document, or WADA entry. Where the indexed literature is silent — long-term human safety, fertility data, hair-related endpoints — the site says so explicitly rather than implying coverage by omission. The platform-overview register (feature cards, comparison tables, spec chips) is a presentational choice; it is not a claim that the compound is itself an approved platform or product.
What this site is not
No clinic. No pharmacy. No storefront. No prescriber. This site gives no medical guidance and opens no door to obtaining CJC-1295. There is no clinical team, no physician on staff, no pharmacist. The compound carries no FDA approval for any indication and is barred under the WADA Code at all times, in and out of competition, for athletes bound by it.